Hinge Health (NYSE:HNGE) Major Shareholder Insight Holdings Group, Llc Sells 224,399 Shares

Hinge Health Inc. (NYSE:HNGE) major shareholder Insight Holdings Group, Llc sold 224,399 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $70.95, for a total transaction of $15,921,109.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Insight Holdings Group, Llc also recently made the following trade(s):

• On Wednesday, June 24th, Insight Holdings Group, Llc sold 390,917 shares of Hinge Health stock. The stock was sold at an average price of $71.15, for a total transaction of $27,813,744.55.
• On Tuesday, June 23rd, Insight Holdings Group, Llc sold 112,477 shares of Hinge Health stock. The stock was sold at an average price of $70.21, for a total transaction of $7,897,010.17.
• On Tuesday, June 16th, Insight Holdings Group, Llc sold 65,581 shares of Hinge Health stock. The stock was sold at an average price of $70.36, for a total value of $4,614,279.16.

Hinge Health Price Performance

Shares of NYSE:HNGE opened at $70.36 on Thursday. The company has a market capitalization of $5.44 billion and a PE ratio of -5.70. The business has a fifty day moving average price of $55.45 and a two-hundred day moving average price of $47.16. Hinge Health Inc. has a 1 year low of $30.08 and a 1 year high of $72.39.

Hinge Health (NYSE:HNGE) last released its earnings results on Tuesday, May 5th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.33. The company had revenue of $182.31 million for the quarter. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The company’s revenue for the quarter was up 47.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.30 earnings per share. Sell-side analysts anticipate that Hinge Health Inc. will post 1.33 earnings per share for the current year.

Hedge Funds Weigh In On Hinge Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its stake in shares of Hinge Health by 160.0% in the fourth quarter. Wells Fargo & Company MN now owns 546 shares of the company’s stock worth $25,000 after purchasing an additional 336 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Hinge Health during the 4th quarter valued at approximately $26,000. First Horizon Corp lifted its stake in shares of Hinge Health by 163.9% during the 4th quarter. First Horizon Corp now owns 855 shares of the company’s stock valued at $40,000 after buying an additional 531 shares in the last quarter. CENTRAL TRUST Co bought a new position in Hinge Health in the 1st quarter worth approximately $37,000. Finally, Aster Capital Management DIFC Ltd bought a new position in Hinge Health in the 3rd quarter worth approximately $49,000.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HNGE. Needham & Company LLC boosted their target price on shares of Hinge Health from $63.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. Weiss Ratings upgraded shares of Hinge Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 6th. Canaccord Genuity Group lifted their price target on shares of Hinge Health from $65.00 to $76.00 and gave the stock a “buy” rating in a report on Monday, June 15th. Robert W. Baird upped their price objective on Hinge Health from $55.00 to $65.00 and gave the company a “neutral” rating in a research note on Wednesday, June 17th. Finally, Stifel Nicolaus set a $79.00 price objective on Hinge Health in a report on Wednesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.80.

Hinge Health News Roundup

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Hinge Health raised its Q2 2026 revenue guidance to $200 million-$202 million, above the Street’s $195 million estimate, and lifted full-year 2026 revenue guidance to $818 million-$824 million versus consensus of $801.6 million, signaling stronger growth expectations.
• Positive Sentiment: The stock continues to benefit from strong prior operating results, including revenue growth of 47.2% in the most recent reported quarter and earnings that beat analyst estimates, which supports the bullish analyst backdrop.
• Neutral Sentiment: Several analysts remain constructive on Hinge Health, with recent price targets in the $79-$90 range and a consensus rating of “Moderate Buy,” suggesting Wall Street still sees upside from current levels.
• Negative Sentiment: Major shareholder Insight Holdings Group sold a large block of shares in multiple June transactions, including 390,917 shares on June 24, 224,399 shares on June 22, and 112,477 shares on June 23, which can weigh on sentiment even though the sales were made under a pre-arranged 10b5-1 plan.
• Negative Sentiment: President James Pursley also sold 33,000 shares on June 22, adding to the cluster of insider selling that may raise concern about valuation after the stock’s recent run-up.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.